Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil dry powder - Liquidia Technologies

Next Previous
Drug Profile

Treprostinil dry powder - Liquidia Technologies

Alternative Names: LIQ-861; YUTREPIA

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Liquidia Technologies
  • Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Pulmonary arterial hypertension

Most Recent Events

  • 12 Mar 2024 The Federal Circuit rejects request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid
  • 25 Jan 2024 The US FDA is unable to issue an action letter on PDUFA date of January 24, 2024 and continues the NDA review for treprostinil dry powder for pulmonary hypertension associated with interstitial lung disease (PH-ILD)
  • 20 Dec 2023 US Federal Circuit affirms earlier Patent Trial and Appeal Board (PTAB) decision to invalidate all claims of United Therapeutics Patent No.10,716,793 ('793 Patent)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top